Lista de obras -

Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability

artículo científico publicado en 2011

An old drug with a new future: bendamustine in multiple myeloma.

artículo científico publicado en 2013

Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia

artículo científico publicado en 2015

B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens

artículo científico publicado en 2006

Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.

artículo científico publicado en 2016

Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).

artículo científico publicado en 2002

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival

artículo científico publicado en 2014

CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL.

artículo científico publicado en 2009

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma

artículo científico publicado en 2012

Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion

artículo científico publicado en 2010

Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses

artículo científico publicado en 2005

Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients

artículo científico publicado en 2014

Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia.

artículo científico publicado en 2012

Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.

artículo científico publicado en 2017

Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience

artículo científico publicado en 2010

Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.

artículo científico publicado en 2016

Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases

artículo científico publicado en 2020

Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia

artículo científico publicado en 2013

Does adiponectin act as an antiangiogenic factor in B-cell chronic lymphocytic leukemia?

artículo científico publicado en 2009

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

artículo científico publicado en 2017

Epigenetic regulation in myelodysplastic syndromes: implications for therapy

artículo científico publicado en 2011

European Myeloma Network guidelines for the management of multiple myeloma-related complications

artículo científico publicado en 2015

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

artículo científico publicado en 2014

Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma

artículo científico publicado en 2002

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques

artículo científico publicado en 2015

Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma

article

High-dose chemotherapy with mitoxantrone + melphalan and autologous stem cell rescue in metastatic breast cancer patients: a study of feasibility and tolerability.

artículo científico publicado en 2003

Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis

article

Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia

artículo científico publicado en 2008

Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma

artículo científico publicado en 2007

Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases

artículo científico publicado en 2014

Janus kinase 2 inhibitors in myeloproliferative disorders

artículo científico publicado en 2010

Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy

artículo científico publicado en 2013

Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.

artículo científico publicado en 2005

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia

artículo científico publicado en 2015

NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome

artículo científico publicado en 2020

Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature

artículo científico publicado en 2007

Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Grupp

artículo científico publicado en 2015

Primary plasma cell leukemia in the era of new drugs: has something changed?

artículo científico publicado en 2011

Promising therapies for the treatment of chronic lymphocytic leukemia

artículo científico publicado en 2015

Prospective study of indolent non-follicular non-Hodgkin's lymphoma: validation of Gruppo Italiano per lo studio dei linfomi (GISL) prognostic criteria for watch and wait policy.

artículo científico publicado en 2002

Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study

artículo científico publicado en 2015

Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma

artículo científico publicado en 2011

Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia

artículo científico publicado en 2011

Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia

artículo científico publicado en 2009

Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment

artículo científico

The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience

article

Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study

artículo científico publicado en 2013

Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need.

artículo científico publicado en 2013

Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma

artículo científico publicado en 2007

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab

scientific article published on 16 September 2020

Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients.

artículo científico publicado en 2016

Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL).

artículo científico publicado en 2011

Lista de obras de

Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability

An old drug with a new future: bendamustine in multiple myeloma.

Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia

B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens

Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.

Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival

CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL.

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma

Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion

Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses

Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients

Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia.

Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.

Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience

Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.

Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases

Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia

Does adiponectin act as an antiangiogenic factor in B-cell chronic lymphocytic leukemia?

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

Epigenetic regulation in myelodysplastic syndromes: implications for therapy

European Myeloma Network guidelines for the management of multiple myeloma-related complications

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques

Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma

High-dose chemotherapy with mitoxantrone + melphalan and autologous stem cell rescue in metastatic breast cancer patients: a study of feasibility and tolerability.

Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis

Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia

Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma

Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases

Janus kinase 2 inhibitors in myeloproliferative disorders

Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy

Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia

NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome

Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature

Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Grupp

Primary plasma cell leukemia in the era of new drugs: has something changed?

Promising therapies for the treatment of chronic lymphocytic leukemia

Prospective study of indolent non-follicular non-Hodgkin's lymphoma: validation of Gruppo Italiano per lo studio dei linfomi (GISL) prognostic criteria for watch and wait policy.

Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study

Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma

Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia

Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia

Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment

The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience

Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study

Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need.

Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab

Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients.

Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL).